TRINITY BIOTECH PLC
Business
Trinity Biotech develops, manufactures, and markets in vitro diagnostic products and wearable biosensors for clinical laboratory and point-of-care testing. Products detect infectious diseases, autoimmune disorders, diabetes markers (HbA1c), haemoglobinopathies, and blood bank screening; the company also develops a continuous glucose monitoring device. Trinity sells through direct sales forces in the United States, Brazil, and select European markets, plus international distributors to approximately 100 countries across the Americas, Europe, and Asia.
Summary from 20-F filed 2026-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $105.17M |
| Total liabilities | $177.15M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is TRINITY BIOTECH PLC's CIK number?
TRINITY BIOTECH PLC's SEC CIK number is 0000888721 (888721). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find TRINITY BIOTECH PLC's SEC filings?
All of TRINITY BIOTECH PLC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.